相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
The mineralocorticoid receptor in chronic kidney disease
Jonatan Barrera-Chimal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet
Pierre Gueneau de Mussy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
Fabio Angeli et al.
CARDIOLOGY AND THERAPY (2021)
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension
Bertram Pitt et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Jonatan Barrera-Chimal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data
Livia Lenzini et al.
PHARMACOLOGICAL RESEARCH (2021)
Pathophysiology of Hypertension The Mosaic Theory and Beyond
David G. Harrison et al.
CIRCULATION RESEARCH (2021)
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease
J. David Smeijer et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2021)
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
George Bakris et al.
HYPERTENSION (2021)
Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
Emily K. McCoy et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2021)
Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
Massimo Volpe et al.
EUROPEAN HEART JOURNAL (2021)
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Alice M. Jackson et al.
EUROPEAN HEART JOURNAL (2021)
The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
Frederic Jaisser et al.
FRONTIERS IN PHARMACOLOGY (2021)
Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx
Erin S. Morgan et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2021)
Targeting angiotensinogen with RNA-based therapeutics
Liwei Ren et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2020)
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
Pierre Verweij et al.
HYPERTENSION (2020)
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease BLOCK-CKD Trial
George Bakris et al.
HYPERTENSION (2020)
Apilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension
Michel Azizi et al.
JOURNAL OF HYPERTENSION (2019)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins A Phase 2, Open-Label, Multicenter, Dose-Titrating Study
Keith C. Ferdinand et al.
CIRCULATION (2019)
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
Patricia N. Sidharta et al.
CLINICAL DRUG INVESTIGATION (2019)
Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension
Frederic Trensz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Treating Disease at the RNA Level with Oligonucleotides
Arthur A. Levin
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials
Renato De Vecchis et al.
CARDIOLOGY RESEARCH (2019)
Update on Endothelin Receptor Antagonists in Hypertension
Michel Burnier
CURRENT HYPERTENSION REPORTS (2018)
Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension
Steven G. Chrysant
JOURNAL OF CLINICAL HYPERTENSION (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
Hypertension
Suzanne Oparil et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Robert M. Carey et al.
HYPERTENSION (2018)
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
Tzung-Dau Wang et al.
HYPERTENSION (2017)
Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension
Gema Ruiz-Hurtado et al.
EUROPEAN HEART JOURNAL (2017)
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study
Bryan Williams et al.
HYPERTENSION (2017)
The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials
Yang Zhao et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2017)
Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolledwith amlodipine monotherapy
Ji-Guang Wang et al.
JOURNAL OF HYPERTENSION (2017)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Xue-Hai Liang et al.
MOLECULAR THERAPY (2017)
Endothelin A receptor antagonists in diabetic kidney disease
Panagiotis I. Georgianos et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2017)
DOCA-Salt Hypertension: an Update
Tyler Basting et al.
CURRENT HYPERTENSION REPORTS (2017)
LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease A Cohort Study
Amanda H. Anderson et al.
ANNALS OF INTERNAL MEDICINE (2015)
Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials
Chirag Bavishi et al.
EUROPEAN HEART JOURNAL (2015)
Interpretation of ambulatory blood pressure profile: a prognostic approach for clinical practice
Fabio Angeli et al.
JOURNAL OF HYPERTENSION (2015)
Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease
Melanie Huettenrauch et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
Fabrice Balavoine et al.
CLINICAL PHARMACOKINETICS (2014)
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
Kazuomi Kario et al.
HYPERTENSION (2014)
Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension
Michael A. Weber et al.
JOURNAL OF CLINICAL HYPERTENSION (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lvana Lazich et al.
SEMINARS IN NEPHROLOGY (2014)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition
Julian Segura et al.
CURRENT HYPERTENSION REPORTS (2011)
Combination Therapy in Hypertension
Alan H. Gradman et al.
JOURNAL OF CLINICAL HYPERTENSION (2011)
At the heart of tissue: endothelin system and end-organ damage
Marc Iglarz et al.
CLINICAL SCIENCE (2010)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
George L. Bakris et al.
LANCET (2010)
Hypertension and the J-Curve
Bryan Williams
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Orally active aminopeptidase A inhibitors reduce blood pressure -: A new strategy for treating hypertension
Laurence Bodineau et al.
HYPERTENSION (2008)
Role of endothelin-1 in clinical hypertension - 20 years on
Neeraj Dhaun et al.
HYPERTENSION (2008)
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Kenneth Jamerson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The burden of blood pressure-related disease - A neglected priority for global health
Vlado Perkovic et al.
HYPERTENSION (2007)
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic - A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
M Rahman et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction
F Amiri et al.
CIRCULATION (2004)
Salt sensitivity of Japanese from the viewpoint of gene polymorphism
T Katsuya et al.
HYPERTENSION RESEARCH (2003)
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
MR Law et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease - Results from the AASK trial
JT Wright et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo
JR Bertrand et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Metabolic regulation of brain Aβ by neprilysin
N Iwata et al.
SCIENCE (2001)
分享论文
